115 related articles for article (PubMed ID: 25154537)
1. Racial/Ethnic disparities in monitoring metabolic parameters for patients with schizophrenia receiving antipsychotic medications.
Phillips KL; Copeland LA; Zeber JE; Stock EM; Tsan JY; MacCarthy AA
Am J Geriatr Psychiatry; 2015 Jun; 23(6):596-606. PubMed ID: 25154537
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.
Hsu C; Ried LD; Bengtson MA; Garman PM; McConkey JR; Rahnavard F
J Am Pharm Assoc (2003); 2008; 48(3):393-400. PubMed ID: 18595825
[TBL] [Abstract][Full Text] [Related]
4. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
5. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia.
Dassori AM; Copeland LA; Zeber JE; Miller AL
Psychiatr Serv; 2011 Jan; 62(1):47-53. PubMed ID: 21209299
[TBL] [Abstract][Full Text] [Related]
6. Racial differences in the use of adjunctive psychotropic medications for patients with schizophrenia.
Mallinger JB; Lamberti SJ
J Ment Health Policy Econ; 2007 Mar; 10(1):15-22. PubMed ID: 17417044
[TBL] [Abstract][Full Text] [Related]
7. Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.
Weissman E; Jackson C; Schooler N; Goetz R; Essock S
Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):201-7. PubMed ID: 22182457
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
[TBL] [Abstract][Full Text] [Related]
9. Racial and ethnic differences in receipt of antidepressants and psychotherapy by veterans with chronic depression.
Quiñones AR; Thielke SM; Beaver KA; Trivedi RB; Williams EC; Fan VS
Psychiatr Serv; 2014 Feb; 65(2):193-200. PubMed ID: 24178411
[TBL] [Abstract][Full Text] [Related]
10. Associations between race and ethnicity and receipt of advice about alcohol use in the Department of Veterans Affairs.
Dobscha SK; Dickinson KC; Lasarev MR; Lee ES
Psychiatr Serv; 2009 May; 60(5):663-70. PubMed ID: 19411355
[TBL] [Abstract][Full Text] [Related]
11. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
Shi L; Ascher-Svanum H; Chiang YJ; Zhao Y; Fonseca V; Winstead D
BMC Psychiatry; 2009 Dec; 9():80. PubMed ID: 20021664
[TBL] [Abstract][Full Text] [Related]
12. Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.
Weissman EM; Zhu CW; Schooler NR; Goetz RR; Essock SM
J Clin Psychiatry; 2006 Sep; 67(9):1323-6. PubMed ID: 17017817
[TBL] [Abstract][Full Text] [Related]
13. Racial and ethnic disparities in Alzheimer's disease pharmacotherapy exposure: an analysis across four state Medicaid populations.
Gilligan AM; Malone DC; Warholak TL; Armstrong EP
Am J Geriatr Pharmacother; 2012 Oct; 10(5):303-12. PubMed ID: 23063286
[TBL] [Abstract][Full Text] [Related]
14. Monitoring for metabolic side effects among outpatients with dementia receiving antipsychotics.
Mittal D; Li C; Viverito K; Williams JS; Landes RD; Thapa PB; Owen R
Psychiatr Serv; 2014 Sep; 65(9):1147-53. PubMed ID: 24829056
[TBL] [Abstract][Full Text] [Related]
15. Associations between Race/Ethnicity, Uterine Fibroids, and Minimally Invasive Hysterectomy in the VA Healthcare System.
Callegari LS; Katon JG; Gray KE; Doll K; Pauk S; Lynch KE; Uchendu US; Zephyrin L; Gardella C
Womens Health Issues; 2019; 29(1):48-55. PubMed ID: 30293778
[TBL] [Abstract][Full Text] [Related]
16. Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system.
Valenstein M; McCarthy JF; Ignacio RV; Dalack GW; Stavenger T; Blow FC
Psychiatr Serv; 2006 Jan; 57(1):70-6. PubMed ID: 16399965
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
Brunero S; Lamont S; Fairbrother G
Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
[TBL] [Abstract][Full Text] [Related]
18. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
[TBL] [Abstract][Full Text] [Related]
19. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in the use of second-generation antipsychotics for the treatment of schizophrenia.
Mallinger JB; Fisher SG; Brown T; Lamberti JS
Psychiatr Serv; 2006 Jan; 57(1):133-6. PubMed ID: 16399976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
